91猫先生

研究方向及研究室特色

研究主轴一：Cathepsin S 与肿瘤免疫调控

探讨 Cathepsin S（CTSS）如何调控蛋白质稳定性与后转译修饰，影响抗原呈现、免疫检查点表达及肿瘤免疫微环境。整合蛋白质体学、多重免疫萤光与多体学分析，系统性解析 CTSS 与免疫细胞浸润的关联，评估其作為预测 PD-1/PD-L1 抑制剂治疗反应之生物标记潜力，為头颈癌免疫治疗提供新靶点。

研究主轴二：Cathepsin S 抑制剂与奈米药物开发应用於精準癌症治疗

开发新型 CTSS 抑制剂与肿瘤微环境响应性奈米载体，提升药物专一性、稳定性与肿瘤累积浓度，减少脱靶毒性。结合电脑辅助药物设计优化抑制剂，评估与免疫检查点抑制剂的协同疗效，整合动物模型与临床资料寻找预测性生物标记，建立基础到临床的完整转译平台。

研究主轴叁：色氨酸代谢与癌症免疫治疗

与成功大學及國際頂尖大學合作，开发新型色氨酸代謝抑制劑，聚焦 滨顿翱1–办测苍耻谤别苍颈苍别 路径在免疫抑制中的角色。筛选出同时抑制 IDO1 与 ABCB1（P-gp）的候选药物，双靶点策略可逆转免疫抑制并克服未来抗药性，提升免疫治疗效果并降低復发风险。

研究主轴四：Cathepsin S 与癌症轉移

探讨 CTSS 如何降解细胞外基质并调控 EMT 訊號，促進癌細胞侵襲与遠端轉移。利用尾靜脈注射与原位移植動物模型，解析 CTSS 对循环肿瘤细胞存活、血管新生及器官定殖的影响，评估 CTSS 抑制剂作為抗转移治疗策略的潜力，為晚期癌症患者提供新型治疗选项。

最近五年所發表論文: (*, Corresponding author):

      1. Chen PC, Chang YC, Ho YY, Tseng KY, Lin KH, Sari S, ?zdemir Z, Reynisson J, Leung E, Cheung CHA*. Discovery of a novel miconazole analogue as a dual apo-IDO1 inhibitor and ABCB1 modulator for cancer immunotherapy and chemosensitizing. European Journal of Pharmaceutical Sciences (2026) 224, 107605 (Impact Factor: 5.1; Ranking: Pharmacology & pharmacy 65/356 (Q1)) (co-first author)
2. Chang YC, Huang WL, Su WC, Cheng FY, Cheung CHA*. BIRC5 promoter-driven nanodrugs suppress BIRC5-positive cancers independent of ABCB1 status. International Journal of Nanomedicine (2026) 21:588571 (Impact Factor: 8.7; Ranking: Pharmacology & pharmacy 17/356 (Q1))
3. Liu CC, Wu CL, Wang CY, Lee JS, Chen PY, Anuraga G, Solomon DD, Qiu LY, Chang YC, Chu JM, Huang CY, Chuang JY, and Chang KY*. Tumor-derived RPS19 engages C5AR1+inflammatory macrophages to drive astrocyte reprogramming and glioblastoma progression. Cell Communication and Signaling. (2026) (Impact Factor: 11.6; Ranking: Cell biology 29/207 (Q1)) 
4. Lin YC, Lin TY, Chang YC, Cheng HC, Hong YK, Aala WJH, Reyes HH, Hou PC, Huang HY, Guevara BEK, Cheung CHA, McGrath JA, Hsu CK*. Synergistic Enhancement of PD-L1 Expression from DNA Repair Dysfunction and UV Exposure in Xeroderma Pigmentosum: Potential Therapeutic Role of PD-L1 Inhibitors. Journal of Dermatological Science. (2026) (Impact Factor: 4.6; Ranking: Dermatology 11/99 (Q1))
5. Chang YC, Chen SJ, Chen SH, Hsiao SY, Chen LH, Chen CH, Liu CC, Chen YW, Liu KJ, Wu SY, Chu JM, Qiu LY, Chiang WF, Hsieh HP, Hsueh WY, Hsiao JR, Shen MR, Chang JY*, and Chang KY*. Unraveling Cathepsin S Regulation in Interleukin-7-mediated Anti-tumor Immunity Reveals its Targeting Potential Against Oral Cancer. Journal of Biomedical Science (2025) 32:69 (Impact Factor: 14.5; Ranking: Medicine, research & experimental 8/191 (Q1)) 
6. Cheng SM, Chang YC, Lin TY, Leung E, Coumar MSC, Cheung CHA*. Did we miss something important? Rethinking the effects of autophagy and mitophagy on DNA damage repair and genomic stability. Journal of Cancer Metastasis and Treatment (2025) 11:16 (Impact Factor: 1.6; Ranking: Oncology 280/333 (Q4))
7. Peng HY, Chang KY, Chang WM, Wu CY, Lee HL, Chang YC, Liu KJ, Shiah SG, Kuo CC, Chang JY. EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. Neoplasia (2025) 66:101193((Impact Factor: 4.8; Ranking: Oncology 92/333 (Q2))
8. Lee CH, Lin YC, Chang YC, Chen OC, Lin KH, Yeh TM, Leung EY, Lin IL, Chen SH, Cheung CHA*. NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells. Journal of Cancer (2025) 16(5):1694-1708 (Impact Factor: 3.4; Ranking: Oncology 148/333 (Q2))
9. Liu CC, Yang WB, Chien CH, Wu CL, Chuang JY, Chen PY, Chu JM, Cheng SM, Qiu LY, Chang YC, Hwang DY, Hung CY, Lee JS, Chang KY*. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity. Cell Death and Disease (2024) 15(6):434 (Impact Factor: 12.2; Ranking: Cell biology 27/207 (Q1))
10. Lin IL, Lin YT, Chang, YC, Kondapuram SK, Lin KH, Chen PC, Kuo CY, Coumar MS, Cheung CHA*. The SMAC mimetic GDC-0152 us a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells. Toxicology and Applied Pharmacology (2024) 5:116888 (Impact Factor: 3.6; Ranking: Toxicology 35/106 (Q2))
11. Chang YC, Shieh MC, Chang YH, Huang WL, Su WC, Cheng FY, Cheung CHA*. Development of a cancer cells self-activating and miR-125a-5p expressing poly-pharmacological nanodrug for cancer treatment. International Journal of Molecular Medicine (2022). 50(2): 102 (Co-first author) (Impact Factor: 8.5; Ranking: Medicine, research & experimental 22/191 (Q1))
12. Chang YC, Cheung CHA*. An updated review of Smac mimetics, LCL161, Birinapant, and GDC- 0152 in cancer treatment. Applied Sciences (2021). 11(1), 335 (Impact Factor: 2.9; Ranking: Engineering, multidisciplinary 78/179 (Q2))
13. Cheng SM, Lin TY, Chang YC, Lin IW, Leung E and Cheung CHA*. YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair. Pharmacological Research (2021). 166:105474 (Impact Factor: 12.2; Ranking: Pharmacology & pharmacy 4/356 (Q1))